Bristol Myers Squibb (BMS), a leading global biopharmaceutical company, has announced the establishment of Singapore as its new Pan Asia Cluster (PAC) hub. This decision, made public on 8 July 2026, coincides with the company’s 60th anniversary in Singapore and is supported by the Singapore Economic Development Board (EDB). The hub aims to accelerate patient access and innovation across the region, enhancing BMS’s commitment to the local life sciences ecosystem.
The new hub will consolidate markets including Hong Kong & Macau, Taiwan, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and the Philippines, employing over 200 staff. BMS plans to leverage this strategic position to strengthen capabilities and talent, with more than 60 clinical trials already underway in the PAC region and five new trials set to commence in Singapore by the end of 2026.
Steve Sugino, Senior Vice President, Asia Pacific, BMS, highlighted the significance of this move, stating, “Our 60-year legacy in Singapore is proof of our long-term commitment to bringing innovative medicines to patients here and across the region.” The establishment of the hub underscores Singapore’s role as a stable and innovative base in Asia, with a strong life sciences ecosystem and skilled talent pool.
Ho Weng Si, Executive Vice President of EDB, expressed support, saying, “The establishment of its new Pan Asia Cluster hub adds to Singapore’s vibrant biomedical sciences ecosystem, and reinforces our role as a trusted base for companies to drive innovation and regional strategies.”
BMS’s initiative is expected to improve patient access to innovative medicines, contributing to better healthcare outcomes in the region.
